J & D Pharmaceuticals is prioritizing its focus on the medical and surgical needs of the military.
J & D Pharma has pioneered groundbreaking formulations of intravenous (IV) and oral salicylsalicylic acid phosphatidylcholine (JD-005). These formulations merge the potential efficacy of JD-004 with the well-established gastrointestinal (GI) safety associated with phosphatidylcholine when combined with NSAIDs. Our focus lies in addressing both acute and chronic traumatic brain injury (TBI) scenarios.
Our proprietary topical liposomal JD-004 cream, lotion, and powder are being developed to help promote rapid wound healing while delivering analgesic activity at the same time. Combined with our IV as well as oral liposomal JD-004 formulations, the burn patient will receive optimal salicylate therapy and potentially have a decreased need for opioids.
Pre-operative, peri-operative, and post-operative analgesic anti-inflammatory treatment is the optimal goal in treating surgical patients. Liposomal JD-005 in intravenous and oral formulations achieves this goal.
J & D Pharmaceuticals has developed a lead compound called JD-005 for use in slowing disease progression of ADPKD in patients starting in childhood and continued into adulthood. JD-005 treatment in the animal model of ADPKLD, next to restoring energy metabolism toward wildtype levels, also affected cell proliferation and inflammation. JD-005 positively affected major dysregulated processes in ADPKD: energy metabolism, cell proliferation, and inflammation, providing more insights into its working mechanisms.
The active moiety of JD-004 is effective in slowing the aging process in the animal model associated with Progeria, an accelerated aging disease of children. It is highly likely that when used in the Progeria children (also known as Hutchinson-Gilford Progeria Syndrome/HGPS), JD-004 will be successful in slowing their accelerated aging process.